Status:
ACTIVE_NOT_RECRUITING
Aleniglipron Phase 2 Body Composition Study
Lead Sponsor:
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions:
Obesity, Overweight, or Chronic Weight Management
Eligibility:
All Genders
18-79 years
Phase:
PHASE2
Brief Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to alenigli...
Eligibility Criteria
Inclusion
- Signed informed consent
- Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2
- Screening HbA1c \<6.5 %
Exclusion
- Previous documented diagnosis of diabetes mellitus
- Self-reported change in body weight \>5% within 3 months before Screening
- Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan
- Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
- Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)
Key Trial Info
Start Date :
August 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2026
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT07169942
Start Date
August 15 2025
End Date
September 1 2026
Last Update
October 31 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States, 85020
2
Research Site
Chicago, Illinois, United States, 60602
3
Research Site
Richfield, Minnesota, United States, 55423
4
Research Site
City of Saint Peters, Missouri, United States, 63303